A meta-analysis comparing buprenorphine to methadone for treatment of opiate dependence.
BACKGROUND
The unique pharmacological properties of buprenorphine may make it a useful maintenance therapy for opiate addiction. This meta-analysis considers the effectiveness of buprenorphine relative to methadone.


METHODS
A systematic literature search identified five randomized clinical trials comparing buprenorphine to methadone. Data from these trials were obtained. Retention in treatment was analyzed with a Cox proportional hazards regression. Urinalyses for opiates were studied with analysis of variance and a common method of handling missing values. A meta-analysis was used to combine these results.


RESULTS
Subjects who received 8-12 mg/day buprenorphine had 1.26 times the relative risk of discontinuing treatment (95% confidence interval 1.01-1.57) and 8.3% more positive urinalyses (95% confidence interval 2.7-14%) than subjects receiving 50-80 mg/day methadone. Buprenophrine was more effective than 20-35 mg/day methadone. There was substantial variation in outcomes in the different trials.


CONCLUSIONS
The variation between trials may be due to differences in dose levels, patient exclusion criteria and provision of psychosocial treatment. The difference in the effectiveness of buprenorphine and methadone may be statistically significant, but the differences are small compared to the wide variance in outcomes achieved in different methadone treatment programs. Further research is needed to determine if buprenorphine treatment is more effective than methadone in particular settings or in particular subgroups of patients.
Barnett
P G
PG
Cooperative Studies Program and Health Economics Resource Center, VA Palo Alto Health Care System, US Department of Veterans Affairs, Menlo Park, CA 94025, USA. paul.barnett@med.va.gov
Rodgers
J H
JH
Bloch
D A
DA
D000704:Analysis of Variance; D002047:Buprenorphine / Q000627:therapeutic use*; D006801:Humans; D008691:Methadone / Q000627:therapeutic use*; D009294:Narcotics / Q000627:therapeutic use* / Q000652:urine; D009293:Opioid-Related Disorders / Q000534:rehabilitation* / Q000652:urine; D010349:Patient Compliance; D010352:Patient Dropouts / Q000706:statistics & numerical data; D016016:Proportional Hazards Models; D016896:Treatment Outcome
D009294:Narcotics; D002047:Buprenorphine; D008691:Methadone